AAV vectors may have utility for gene therapy but heretofore a significant obstacle
has been the inability to generate sufficient quantities of such recombinant vectors
in amounts that would be clinically useful for human gene therapy application.
Stable AAV packaging cell lines have been elusive, mainly due to the activities
of Rep protein, which down-regulates its own expression and can negatively affect
the host cell. This invention provides packaging systems and processes for packaging
AAV vectors that effectively circumvent these problems and that allow for substantially
increased packaging efficiency.
